Compare Amphastar Pharmaceuticals Inc (AMPH) vs Intuit Inc. (INTU) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Intuit (INTU) trades at $274.96, up 0.58% on the day, with a neutral technical signal and bearish moving averages. The stock is near its 52-week low of $275.00, reflecting recent pressure. Fundamentally, the company shows strong revenue growth, with 2025 revenue at $18.83B and net income of $3.87B, and has beaten earnings estimates in recent quarters. However, sentiment is mixed due to ongoing securities fraud investigations related to pricing issues, contributing to a significant stock decline over the past year.

The outlook for Intuit is cautiously optimistic, with robust fundamentals and a consensus analyst price target of $433.69 suggesting substantial upside. Key opportunities include continued earnings growth and AI-driven product expansion. Risks include legal uncertainties from fraud probes, competitive pressures, and potential regulatory scrutiny. Investors should weigh strong financial performance against near-term sentiment headwinds.